Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders

The endogenous opioid system (EOS) is considered being a crucial element involved in the pathophysiology of irritable bowel syndrome (IBS) as it regulates gastrointestinal (GI) homeostasis through modulation of motility and water and ion secretion/absorption. Along with opioid receptors (ORs), the following components of EOS can be distinguished: 1. endogenous opioid peptides (EOPs), namely enkephalins, endorphins, endomorphins and dynorphins, and 2. peptidases, which regulate the metabolism (synthesis and degradation) of EOPs. Enkephalins, which are δ‐opioid receptors agonists, induce significant effects in the GI tract as they act as potent pro‐absorptive neurotransmitters. The action of enkephalins and other EOPs is limited, since EOPs are easily and rapidly inactivated by a natural metalloendopeptidase (enkephalinase/neprilysin) and aminopeptidase N. Studies show that the activity of EOPs can be enhanced by inhibition of these enzymes. In this review, we discuss the antidiarrheal and antinociceptive potential of enkephalinase inhibitors. Furthermore, our review is to answer the question whether enkephalinase inhibitors may be helpful in the future treatment of diarrhea predominant functional GI disorders.

[1]  J. Fichna,et al.  Antinociceptive potency of enkephalins and enkephalinase inhibitors in the mouse model of colorectal distension—proof‐of‐concept , 2018, Chemical biology & drug design.

[2]  Lin Chang,et al.  FUNCTIONAL BOWEL DISORDERS , 2018, The American Journal of Gastroenterology.

[3]  Lin Chang,et al.  Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice , 2017, Therapeutic advances in gastroenterology.

[4]  J. Fichna,et al.  Review: The Role of MOP and DOP Receptors in Treatment of Diarrheapredominant Irritable Bowel Syndrome. , 2016, Mini-Reviews in Medical Chemistry.

[5]  B. Roques,et al.  Preventive and alleviative effects of the dual enkephalinase inhibitor (Denki) PL265 in a murine model of neuropathic pain. , 2016, European journal of pharmacology.

[6]  J. Fichna,et al.  Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome , 2016, Therapeutics and clinical risk management.

[7]  L. Turner,et al.  Eluxadoline for Irritable Bowel Syndrome with Diarrhea. , 2016, The New England journal of medicine.

[8]  A. Akobeng,et al.  Racecadotril for acute diarrhoea in children: systematic review and meta-analyses , 2015, Archives of Disease in Childhood.

[9]  L. Turner,et al.  Su1378 Robustness of Eluxadoline for the Treatment of Irritable Bowel Syndrome With Diarrhea: Results From Phase 3 Composite Endpoint Assessments , 2015 .

[10]  W. Chey,et al.  316 Eluxadoline Demonstrates Sustained Efficacy for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome in Phase 3 Clinical Trials , 2015 .

[11]  W. Krajewska,et al.  Orally administered novel cyclic pentapeptide P‐317 alleviates symptoms of diarrhoea‐predominant irritable bowel syndrome , 2015, The Journal of pharmacy and pharmacology.

[12]  J. Andrews,et al.  Immune derived opioidergic inhibition of viscerosensory afferents is decreased in Irritable Bowel Syndrome patients , 2014, Brain, Behavior, and Immunity.

[13]  P. Lehert,et al.  Racecadotril in the Treatment of Acute Diarrhoea in Adults. An Individual Patient Data Based Meta-Analysis , 2014 .

[14]  P. Lehert,et al.  Racecadotril Efficacy in the Symptomatic Treatment of Adult Acute Diarrhoea: A Systematic Review and Meta-Analysis , 2014 .

[15]  M. Heitkemper,et al.  Anxiety, Depression, and Catecholamine Levels After Self-Management Intervention in Irritable Bowel Syndrome , 2014, Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates.

[16]  J. Andrews,et al.  Immune Activation in Irritable Bowel Syndrome: Can Neuroimmune Interactions Explain Symptoms? , 2013, The American Journal of Gastroenterology.

[17]  J. Fichna,et al.  Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives , 2013, Journal of Gastroenterology.

[18]  H. Shimada,et al.  Relationship Between Cognitive Factors and Anxiety in Individuals with Irritable Bowel Syndrome , 2012, International Journal of Behavioral Medicine.

[19]  Sulie L. Chang,et al.  Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR. , 2012, Drug and alcohol dependence.

[20]  M. Eberlin,et al.  A Comprehensive Review of the Pharmacodynamics, Pharmacokinetics, and Clinical Effects of the Neutral Endopeptidase Inhibitor Racecadotril , 2012, Front. Pharmacol..

[21]  J. Andrews,et al.  Sensory neuro-immune interactions differ between Irritable Bowel Syndrome subtypes , 2012, Gut.

[22]  O. Levran,et al.  The genetics of the opioid system and specific drug addictions , 2012, Human Genetics.

[23]  B. Roques,et al.  Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain , 2012, Nature Reviews Drug Discovery.

[24]  A. Mangel,et al.  Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review , 2012, Clinical and experimental gastroenterology.

[25]  W. Chey,et al.  The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis , 2012, The American Journal of Gastroenterology.

[26]  E. Rabiner,et al.  Opioids and anxiety , 2011, Journal of psychopharmacology.

[27]  B. Kieffer,et al.  Localization and regulation of fluorescently labeled delta opioid receptor, expressed in enteric neurons of mice. , 2011, Gastroenterology.

[28]  T. Hökfelt,et al.  Coexpression of δ- and μ-opioid receptors in nociceptive sensory neurons , 2010, Proceedings of the National Academy of Sciences.

[29]  G. De Sarro,et al.  Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes , 2010, European Journal of Clinical Pharmacology.

[30]  F. Shanahan,et al.  A Molecular Analysis of Fecal and Mucosal Bacterial Communities in Irritable Bowel Syndrome , 2010, Digestive Diseases and Sciences.

[31]  David Julius,et al.  Cellular and Molecular Mechanisms of Pain , 2009, Cell.

[32]  T. Wittmann,et al.  Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice , 2009, PAIN®.

[33]  K. Thibault,et al.  Antinociceptive and anti-allodynic effects of oral PL37, a complete inhibitor of enkephalin-catabolizing enzymes, in a rat model of peripheral neuropathic pain induced by vincristine. , 2008, European journal of pharmacology.

[34]  M. Camilleri,et al.  Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. , 2008, Gastroenterology.

[35]  A. Mangel,et al.  Asimadoline in the treatment of irritable bowel syndrome , 2008, Expert opinion on investigational drugs.

[36]  A. Lembo.  Peripheral Opioids for Functional GI Disease: A Reappraisal , 2006, Digestive Diseases.

[37]  J. Bienenstock,et al.  Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats , 2005, Gut.

[38]  M. Shieh,et al.  A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults. , 2005, World journal of gastroenterology.

[39]  F. Shanahan,et al.  Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. , 2005, Gastroenterology.

[40]  A. Palva,et al.  Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome--a longitudinal study in IBS and control subjects. , 2005, FEMS immunology and medical microbiology.

[41]  T. Mach.  The brain-gut axis in irritable bowel syndrome--clinical aspects. , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[42]  D. Prado.  A Multinational Comparison of Racecadotril and Loperamide in the Treatment of Acute Watery Diarrhoea in Adults , 2002 .

[43]  M Pappagallo,et al.  Incidence, prevalence, and management of opioid bowel dysfunction. , 2001, American journal of surgery.

[44]  M. Denavit-Saubié,et al.  Effects of the potent analgesic enkephalin-catabolizing enzyme inhibitors RB101 and kelatorphan on respiration , 2001, Pain.

[45]  D. Prado,et al.  A multinational comparison of racecadotril and loperamide in the treatment of acute watery diarrhoea in adults. , 2000, Scandinavian journal of gastroenterology.

[46]  J. Lecomte,et al.  Comparison of racecadotril and loperamide in adults with acute diarrhoea , 1999, Alimentary pharmacology & therapeutics.

[47]  P. Raibaud,et al.  Effects of racecadotril and loperamide on bacterial proliferation and on the central nervous system of the newborn gnotobiotic piglet , 1999, Alimentary pharmacology & therapeutics.

[48]  J. Lecomte,et al.  Racecadotril versus placebo in the treatment of acute diarrhoea in adults , 1999, Alimentary pharmacology & therapeutics.

[49]  R. Sewell,et al.  The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds , 1998, British journal of pharmacology.

[50]  P. Coric,et al.  Pain-suppressive effects on various nociceptive stimuli (thermal, chemical, electrical and inflammatory) of the first orally active enkephalin-metabolizing enzyme inhibitor RB 120 , 1997, Pain.

[51]  H. Akil,et al.  Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract , 1997, Neuroscience.

[52]  S. Lewis,et al.  Stool form scale as a useful guide to intestinal transit time. , 1997, Scandinavian journal of gastroenterology.

[53]  Brigitte L. Kieffer,et al.  Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene , 1996, Nature.

[54]  B. Roques,et al.  The Dual Peptidase Inhibitor RB101 Induces a Long‐Lasting Increase in the Extracellular Level of Met‐Enkephalin‐Like Material in the Nucleus Accumbens of Freely Moving Rats , 1996, Journal of neurochemistry.

[55]  M. Gershwin,et al.  Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. , 1996, The American journal of gastroenterology.

[56]  M. Fournié-Zaluski,et al.  Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation , 1994, Pain.

[57]  J. Poupaert,et al.  Analgesic potency of S-acetylthiorphan after intravenous administration to mice. , 1993, European journal of pharmacology.

[58]  R. Ekman,et al.  Decreased cerebrospinal fluid beta-endorphin and increased pain sensitivity in patients with functional abdominal pain. , 1993, Scandinavian journal of gastroenterology.

[59]  J. Schwartz,et al.  The enkephalinase inhibitor, acetorphan, in acute diarrhoea. A double-blind, controlled clinical trial versus loperamide. , 1993, Scandinavian journal of gastroenterology.

[60]  M. Fournié-Zaluski,et al.  Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. , 1993, Pharmacological reviews.

[61]  M. Fournié-Zaluski,et al.  Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine. , 1992, European journal of pharmacology.

[62]  M. Fournié-Zaluski,et al.  Lack of physical dependence in mice after repeated systemic administration of the mixed inhibitor prodrug of enkephalin-degrading enzymes, RB101. , 1992, European journal of pharmacology.

[63]  F Noble,et al.  "Mixed inhibitor-prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes. , 1992, Journal of medicinal chemistry.

[64]  J. Schwartz,et al.  Effects of acetorphan, an antidiarrhoeal enkephalinase inhibitor, on oro‐caecal and colonic transit times in healthy volunteers , 1992, Alimentary pharmacology & therapeutics.

[65]  J. Schwartz,et al.  Effects of acetorphan, an enkephalinase inhibitor, on experimental and acute diarrhoea. , 1992, Gut.

[66]  R. Przewłocki,et al.  Gene expression and localization of opioid peptides in immune cells of inflamed tissue: Functional role in antinociception , 1992, Neuroscience.

[67]  S. Turcaud,et al.  Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. , 1992, The Journal of pharmacology and experimental therapeutics.

[68]  T. Yaksh,et al.  Effects of [N-(L-(1-carboxy-2-phenyl)ethyl]-L-phenylalanyl-beta-alanine (SCH32615), a neutral endopeptidase (enkephalinase) inhibitor, on levels of enkephalin, encrypted enkephalins and substance P in cerebrospinal fluid and plasma of primates. , 1991, The Journal of pharmacology and experimental therapeutics.

[69]  R. Przewłocki,et al.  Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[70]  R. Ardaillou,et al.  Stereoselective protection of exogenous and endogenous atrial natriuretic factor by enkephalinase inhibitors in mice and humans. , 1990, European journal of pharmacology.

[71]  M. Fournié-Zaluski,et al.  Potent antinociceptive effects of Kelatorphan (a highly efficient inhibitor of multiple enkephalin-degrading enzymes) systemically administered in normal and arthritic rats , 1989, Brain Research.

[72]  B. Roques,et al.  New kelatorphan-related inhibitors of enkephalin metabolism: improved antinociceptive properties. , 1989, Journal of medicinal chemistry.

[73]  J. Schwartz,et al.  Role of endogenous enkephalins in locomotion and nociception studied with peptidase inhibitors in two inbred strains of mice (C57BL/6J AND DBA/2J) , 1989, Neuropharmacology.

[74]  J. Schwartz,et al.  Naloxone-reversible antidiarrheal effects of enkephalinase inhibitors. , 1987, European journal of pharmacology.

[75]  M. Leboyer,et al.  Pharmacological properties of acetorphan, a parenterally active "enkephalinase" inhibitor. , 1986, The Journal of pharmacology and experimental therapeutics.

[76]  B. Roques,et al.  Analgesic effects of kelatorphan, a new highly potent inhibitor of multiple enkephalin degrading enzymes. , 1984, European journal of pharmacology.

[77]  G. Guilbaud,et al.  The analgesic effects of morphine, but not those of the enkephalinase inhibitor thiorphan, are enhanced in arthritic rats , 1983, Brain Research.

[78]  J. Schwartz,et al.  The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice , 1980, Nature.

[79]  R. Spiller,et al.  Bowel Disorders , 2010, The American Journal of Gastroenterology.

[80]  R. Dehaven,et al.  The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor. , 2008, Pharmacology & therapeutics.

[81]  D. Ardid,et al.  Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors , 2007, Nature Medicine.

[82]  A. De Luca,et al.  Insights into opioid action in the intestinal tract. , 1996, Pharmacology & therapeutics.